Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors
Silexion Therapeutics (NASDAQ: SLXN) has appointed Prof. Amnon Peled as an independent director to its Board of Directors. Prof. Peled, a globally recognized authority in stem cell biology, immunology, and cancer therapeutics, will serve on the company's audit, compensation, and nominating and corporate governance committees. The appointment strengthens Silexion's scientific expertise as it develops RNA interference (RNAi) therapies for KRAS-driven cancers.
The Board unanimously approved his appointment, citing his extensive experience in advancing novel cancer therapies from discovery to FDA approval. The appointment also ensures Silexion's compliance with Nasdaq's listing requirements by maintaining a fully constituted audit committee.
Silexion Therapeutics (NASDAQ: SLXN) ha nominato Prof. Amnon Peled come direttore indipendente nel suo Consiglio di Amministrazione. Il Prof. Peled, autorità riconosciuta a livello globale nella biologia delle cellule staminali, immunologia e terapie contro il cancro, farà parte dei comitati di revisione contabile, compenso, e di nomina e governance aziendale della compagnia. Questa nomina rafforza l'expertise scientifica di Silexion mentre sviluppa terapie di interferenza dell'RNA (RNAi) per i tumori guidati da KRAS.
Il Consiglio ha approvato all'unanimità la sua nomina, citando la sua vasta esperienza nel portare avanti nuove terapie contro il cancro dalla scoperta all'approvazione da parte della FDA. La nomina garantisce anche la conformità di Silexion ai requisiti di quotazione di Nasdaq, mantenendo un comitato di revisione contabile completamente costituito.
Silexion Therapeutics (NASDAQ: SLXN) ha nombrado al Prof. Amnon Peled como director independiente en su Junta Directiva. El Prof. Peled, una autoridad de reconocimiento mundial en biología de células madre, inmunología y terapias contra el cáncer, formará parte de los comités de auditoría, compensación y nominación y gobernanza corporativa de la empresa. La designación refuerza la experiencia científica de Silexion mientras desarrolla terapias de interferencia de ARN (RNAi) para cánceres impulsados por KRAS.
La Junta aprobó su nombramiento por unanimidad, citando su amplia experiencia en el avance de nuevas terapias contra el cáncer desde el descubrimiento hasta la aprobación de la FDA. La designación también garantiza que Silexion cumple con los requisitos de cotización de Nasdaq al mantener un comité de auditoría completamente constituido.
사일렉시온 테라퓨틱스 (NASDAQ: SLXN)는 암논 펠레드 교수를 독립 이사로 이사회의 구성원으로 임명했습니다. 펠레드 교수는 줄기 세포 생물학, 면역학 및 암 치료 분야에서 세계적으로 인정받는 권위자이며, 회사의 감사, 보상, 및 임원 및 기업 거버넌스 위원회에서 활동할 것입니다. 이 임명은 사일렉시온이 KRAS 주도 암에 대한 RNA 간섭(RNAi) 치료제를 개발하는 데 있어 과학적 전문성을 강화합니다.
이사회는 그의 임명을 만장일치로 승인하며, 신약 치료법의 발견에서 FDA 승인까지의 광범위한 경험을 강조했습니다. 이 임명은 완전한 구성의 감사 위원회를 유지하여 사일렉시온이 나스닥 상장 요건을 준수하도록 보장합니다.
Silexion Therapeutics (NASDAQ: SLXN) a nommé le Prof. Amnon Peled en tant que directeur indépendant au sein de son Conseil d'Administration. Le Prof. Peled, une autorité reconnue mondialement dans le domaine de la biologie des cellules souches, de l'immunologie et des thérapies contre le cancer, siégera aux comités d'audit, de rémunération ainsi qu'aux comités de nomination et de gouvernance d'entreprise de la société. Cette nomination renforce l'expertise scientifique de Silexion alors qu'elle développe des thérapies par interférence de l'ARN (RNAi) pour les cancers à médiation KRAS.
Le Conseil a unanimement approuvé sa nomination, citant son expérience considérable dans l'avancement de nouvelles thérapies contre le cancer, de la découverte à l'approbation par la FDA. La nomination garantit également que Silexion respecte les exigences de cotation de Nasdaq en maintenant un comité d'audit entièrement constitué.
Silexion Therapeutics (NASDAQ: SLXN) hat Prof. Amnon Peled zum unabhängigen Direktor in seinen Vorstand berufen. Prof. Peled, eine weltweit anerkannte Autorität in der Biologie von Stammzellen, Immunologie und Krebstherapien, wird in den Prüfungsausschüssen, Vergütungsausschüssen sowie dem Nominierungs- und Unternehmensführungsausschuss des Unternehmens tätig sein. Die Ernennung stärkt die wissenschaftliche Expertise von Silexion bei der Entwicklung von RNA-Interferenz (RNAi)-Therapien für KRAS-gesteuerte Krebserkrankungen.
Der Vorstand hat seine Ernennung einstimmig genehmigt und dabei seine umfangreiche Erfahrung bei der Umsetzung neuartiger Krebstherapien von der Entdeckung bis zur FDA-Zulassung hervorgehoben. Die Ernennung gewährleistet zudem, dass Silexion die Anforderungen für die Nasdaq-Notierung erfüllt, indem ein voll besetzter Prüfungsausschuss aufrechterhalten wird.
- Appointment of globally recognized scientific authority strengthens company's expertise in cancer therapeutics
- Maintains Nasdaq listing compliance through fully constituted audit committee
- Adds valuable experience in FDA approval processes and clinical development pathways
- None.
Prof. Peled, a globally recognized scientific authority who has been involved in multiple successful publicly traded bio-pharma companies, will assist Silexion as it advances its RNAi platform and next-generation therapies targeting KRAS mutations
Cayman Islands, December 10, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the appointment of Prof. Amnon Peled as an independent director to its Board of Directors. Prof. Peled, a globally recognized authority in stem cell biology, immunology, and cancer therapeutics who has been involved in numerous successful publicly traded bio-pharma companies, will also serve on the Company’s audit, compensation, and nominating and corporate governance committees. The Board unanimously approved his appointment, citing his decades of experience in advancing novel cancer therapies from discovery to FDA approval.
Ilan Hadar, Chairman and CEO of Silexion, commented: “We are thrilled to welcome Prof. Peled to our Board of Directors. His unparalleled expertise in cancer biology, stem cell mobilization, and therapeutic development will be invaluable as Silexion continues to advance its pipeline of RNAi-based therapies for difficult-to-treat cancers. Prof. Peled’s track record in translating innovative science into impactful clinical outcomes aligns perfectly with our mission to address unmet needs in oncology.”
“I am excited to join Silexion at such a pivotal time in its journey,” said Prof. Amnon Peled. “The Company’s RNAi platform holds tremendous promise for addressing some of the most challenging oncology indications. I look forward to contributing my expertise to help advance Silexion’s innovative pipeline and drive meaningful impact for patients.”
Prof. Peled’s appointment reinforces Silexion’s commitment to scientific and strategic excellence as it advances its RNAi platform and next-generation therapies targeting KRAS mutations. His extensive experience in clinical development and regulatory pathways will contribute to Silexion’s mission of delivering innovative solutions for patients facing the most challenging cancers. Prof. Peled’s appointment also fills its current board vacancy, ensuring Silexion remains in compliance with Nasdaq’s listing requirements, including having a fully constituted audit committee.
About Prof. Amnon Peled
Prof. Peled serves as the Director of the Gene Therapy Institute at Hadassah Medical Center in Jerusalem, where his research focuses on cytokine roles in hematopoietic stem cell biology, inflammation, and cancer. Over his 28-year career, he has led groundbreaking research into the chemokine receptor CXCR4, a key player in stem cell mobilization and cancer. Prof. Peled has authored over 120 scientific publications and holds more than 200 patents and patent applications related to therapeutic applications in stem cell biology, immunology, and cancer.
Prof. Peled’s contributions to biotechnology include close collaborations with leading Israeli biotech companies such as Biokine Therapeutics, BiolineRX (NASDAQ: BLRX), Gamida Cell, KAHR Medical, and AlonBio. He is the founder of Biokine Therapeutics, AlonBio, and SakuraBio. His leadership in the development of the CXCR4 antagonist BKT140/BL8040 and Gamida Cell’s NK and cord blood stem cell expansion technologies has resulted in multiple FDA approvals. Prof. Peled earned his Ph.D. from the Weizmann Institute of Science and conducted postdoctoral research at Harvard Medical School and Millennium Pharmaceuticals, Inc.
About Silexion Therapeutics
Silexion Therapeutics (NASDAQ: SLXN) is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, the most common oncogenic driver in human cancers. The company's first-generation product, LODER™, has shown promising results in a Phase 2 trial for non-resectable pancreatic cancer. Silexion is also advancing its next-generation siRNA candidate, SIL-204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies. The company remains committed to pushing the boundaries of therapeutic innovation in oncology, with a focus on improving outcomes for patients with difficult-to-treat cancers. For more information please visit: https://silexion.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this communication, including statements regarding Silexion’s directors, compliance with Nasdaq listing requirements, share price, business strategy, research and development plans, anticipated milestones, expected clinical and preclinical advancements, and management’s objectives for future operations, are forward-looking statements. These forward-looking statements are generally identified by terminology such as “may,” “should,” “could,” “might,” “plan,” “possible,” “project,” “strive,” “budget,” “forecast,” “expect,” “intend,” “will,” “estimate,” “anticipate,” “believe,” “predict,” “potential,” or “continue,” or the negatives of these terms or variations of them or similar terminology. Forward-looking statements include, without limitation, Silexion’s expectations regarding the progression of its clinical and preclinical programs, pipeline of RNAi-based therapies, contributions of members of its Board of Directors, financing prospects, future market conditions, expected regulatory filings, and other potential developments related to its research pipeline and business strategy. Forward-looking statements involve a number of risks, uncertainties, and assumptions, and actual results or events may differ materially from those projected or implied in such statements. Important factors that could cause such differences include, but are not limited to: (i) Silexion’s ability to realize the anticipated benefits of being a public company, which may be impacted by competition, operational challenges, the retention of key personnel, and the costs associated with public listing; (ii) risks related to Silexion’s ability to advance its lead programs, including LODER™ and SIL-204, through clinical development successfully and in a timely manner; (iii) the potential impact of the Company’s recent reverse share split on the Company’s share price and its ability to maintain compliance with Nasdaq listing requirements; (iv) the potential impact of the recent reverse share split on Silexion’s ability to successfully raise capital in the near future; (v) changes in regulatory requirements or the potential for regulatory delays; (vi) Silexion’s ability to maintain and expand its intellectual property portfolio; (vii) the availability and terms of additional capital needed to fund ongoing research and development activities and operational expenses; (viii) the evolving market for RNA interference (RNAi) therapies and the competitive landscape in oncology; (ix) the possibility that Silexion may not achieve anticipated milestones within expected timelines, including initiation of Phase 2/3 clinical trials for SIL-204; (x) risks associated with reliance on third-party manufacturers and collaborators for development and commercialization efforts; and (xi) other risks and uncertainties as detailed in the documents filed or to be filed with the SEC by Silexion, including the definitive proxy statement on Schedule 14A filed on October 22, 2024, the current report on Form 8-K filed on August 21, 2024, and the Form S-1 registration statement filed on October 31, 2024. Silexion cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information available as of the date a forward-looking statement is made. Forward-looking statements set forth herein speak only as of the date they are made. Silexion undertakes no obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs, except as otherwise required by law.
Contacts
Silexion Therapeutics Corp
Ms. Mirit Horenshtein Hadar, CFO
mirit@silexion.com
ARX | Capital Markets Advisors
North American Equities Desk
silexion@arxadvisory.com
FAQ
Who is the new board member appointed to Silexion Therapeutics (SLXN)?
What committees will Prof. Peled serve on at Silexion Therapeutics (SLXN)?
How does Prof. Peled's appointment affect Silexion's (SLXN) Nasdaq compliance?
What type of therapies is Silexion Therapeutics (SLXN) developing?
